Co-Diagnostics, Inc. ownership disclosure: a Schedule 13G filed by Jane Street Group, LLC and its subsidiaries reports 236,359 shares of Common Stock (CUSIP 189763204) representing 6.4% of the class as of 05/28/2026. The filing attributes shared voting and shared dispositive power over those 236,359 shares. Subsidiary breakdown: Jane Street Capital, LLC holds 189,817 shares (5.2%) and Jane Street Global Trading, LLC holds 46,542 shares (1.3%). The schedule is signed by Jeremy Kahn on 06/03/2026.
Positive
None.
Negative
None.
Insights
Jane Street entities report a 6.4% beneficial stake in CODX with shared voting/dispositive power.
The Schedule 13G lists an aggregated beneficial ownership of 236,359 shares of Common Stock (CUSIP 189763204) as of 05/28/2026, showing shared voting and dispositive authority rather than sole control. The filing identifies two subsidiaries and provides per-entity share counts.
Signatures are dated 06/03/2026. Subsequent regulatory filings would show any change in percentage or voting status; cash-flow treatment or sale intent is not stated in the provided excerpt.
Key Figures
Reporting date:05/28/2026Aggregate beneficial ownership:236,359 sharesPercent of class:6.4%+3 more
6 metrics
Reporting date05/28/2026Ownership reported as of this date
Aggregate beneficial ownership236,359 sharesTotal reported by Jane Street entities as of 05/28/2026
Percent of class6.4%Percentage of Common Stock represented by 236,359 shares
Jane Street Capital holding189,817 sharesJane Street Capital, LLC as reported (5.2%)
Jane Street Global Trading holding46,542 sharesJane Street Global Trading, LLC as reported (1.3%)
Signature date06/03/2026Signed by Jeremy Kahn (Authorized Signatory)
"Name of form shown in metadata and filing header"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Shared dispositive powerfinancial
"Item 4 shows Shared Dispositive Power 236,359.00"
Beneficially ownedregulatory
"Item 4(a) Amount beneficially owned: 236,359.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Co-Diagnostics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
189763204
(CUSIP Number)
05/28/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
189763204
1
Names of Reporting Persons
JANE STREET GROUP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
236,359.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
236,359.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
236,359.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.4 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP Number(s):
189763204
1
Names of Reporting Persons
Jane Street Capital, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
189,817.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
189,817.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
189,817.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
BD
SCHEDULE 13G
CUSIP Number(s):
189763204
1
Names of Reporting Persons
Jane Street Global Trading, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
46,542.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
46,542.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
46,542.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Co-Diagnostics, Inc.
(b)
Address of issuer's principal executive offices:
2401 S FOOTHILL DRIVE, SUITE D, SALT LAKE CITY, UTAH, 84109.
Item 2.
(a)
Name of person filing:
Jane Street Group, LLC;
Jane Street Capital, LLC;
Jane Street Global Trading, LLC
(b)
Address or principal business office or, if none, residence:
Jane Street Group, LLC
250 Vesey Street 6th Floor
New York, NY 10281
Jane Street Capital, LLC
250 Vesey Street 6th Floor
New York, NY 10281
Jane Street Global Trading, LLC
250 Vesey Street 6th Floor
New York, NY 10281
(c)
Citizenship:
See Item 4 of Cover Page
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
189763204
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
236,359.00
(b)
Percent of class:
6.4%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
236,359.00
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
236,359.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Subsidiary
Jane Street Capital, LLC
Jane Street Global Trading, LLC
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does Jane Street report in Co-Diagnostics (CODX)?
Jane Street reports beneficial ownership of 236,359 shares of Co-Diagnostics Common Stock, representing 6.4% of the class as of 05/28/2026. The filing lists shared voting and dispositive power over these shares.
How are the 236,359 CODX shares allocated among Jane Street entities?
The filing attributes 189,817 shares (5.2%) to Jane Street Capital, LLC and 46,542 shares (1.3%) to Jane Street Global Trading, LLC, totaling 236,359 shares (6.4%) as of 05/28/2026.
What voting and disposition powers are reported for the CODX shares?
The Schedule 13G shows 0 shares with sole voting or dispositive power and 236,359 shares with shared voting and shared dispositive power, per the Item 4 ownership table in the filing.
When was the Schedule 13G for CODX signed and filed?
The signatures on the filing are dated 06/03/2026, and the ownership is reported as of 05/28/2026. The filing is signed by Jeremy Kahn as an authorized signatory for the reporting entities.
Does the filing indicate Jane Street will sell or buy CODX shares?
The provided Schedule 13G excerpt reports beneficial ownership and voting/dispositive power only; it does not state any plans to purchase or sell shares or describe cash-flow treatment for the holdings.
